Monthly Archives: June 2020

LRG Webcast Series: GIST: How to Understand Your Pathology Report

In this webinar, we discussed how to interpret your pathology report. We covered interpretation of all parts of a pathology report, beginning with understanding the final diagnosis and diagnostic comment.

By |2020-07-20T10:42:19-04:00June 30th, 2020|GIST Education, Mutations, Webcast|

Blueprint Medicines Announces Publication in The Lancet Oncology

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

By |2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Long-Term Survivor Stories – Chuck Korte & Dina Wiley

For GIST patients, long term survival is the ultimate goal. A number of factors may influence long term survival – some of these are demographic and clinical, like mutational subtype and genetic factors. However, there are a number of others that are perhaps more subtle, such as lifestyle, attitude, and access to treatment, experts, and advice.

By |2021-11-19T17:04:26-05:00June 25th, 2020|Member Stories, News, Newsletter|
Go to Top